POZ Community Forums
Meds, Mind, Body & Benefits => Research News & Studies => Topic started by: geobee on May 05, 2014, 01:55:16 pm
-
From Quest/San Francisco.
Dear Quest Email Recipients,
We are pleased to announce the opening of a new one pill once/day study of Tivicay combined with epzicom called the "Switch" study. Tivicay is the new integrase inhibitor from GSK.
The new combo avoids the CNS toxicity of Atripla, the bone and kidney toxicity of Truvada, the lipodystrophy changes associated with Protease Inhibitors, and doesn't require ritonavir (or cobicistat) to shut down liver metabolism to boost blood levels. In short, this combo is arguably the best regimen for HIV ever developed.
The study is open to folks who are on their first or second HIV regimen. If you would be interested in receiving more information or setting up a screening visit to see if you are eligible, please contact Eileen Glutzer at 415-353-0212 or Eileen@QuestClinical.com
As always, it is an honor to be of service....
Dr Jay
-
This note certainly talks up the wonders of Epzicom, but there are reasons why Truvada is the NRTI backbone of choice in the US -- not Epzicom -- even with the bone/kidney issues. Not taking anything away from Tivicay, but I wonder how popular this particular combo will prove to be.
-
I am in a similar european only study from ViiV. They are so convinced of Tivicay/Epzicom (Kivexa)that they didnt want to draw blood within the first 3 months. I was told that the Truvada side effects (kidneys, bones) dont happen with these drugs. The first 2 month went very well so far. Despite I wait for TAF, but it is not available yet.
The problem of Epzicom is the necessary genetic test, or You can get an allergic shock.
Anyway, GSK has already a better drug than Tivicay in the Pipeline.
The LATTE II study with monthly injections of GSK744 will start soon. It' s Your Chance if You are Treatment-naive, CD over200 and VL over 1.000. :) All others have to wait until 2020.
http://www.mmrf.org/research/hivaids.html (http://www.mmrf.org/research/hivaids.html)
http://clinicaltrials.gov/ct2/show/NCT02120352?term=GSK744&rank=1 (http://clinicaltrials.gov/ct2/show/NCT02120352?term=GSK744&rank=1)
-
6 more years until the first monthly injections hit the market? :-\
That's quite a while to wait. I was hoping they would get available sooner...
-
Anyway, GSK has already a better drug than Tivicay in the Pipeline.
Better in what way? GSK744 is the same drug as Tivicay just repackaged as an injectable.
-
The difference seems to be tiny, :) but they have different formulas: DTG
C20H19F2N3O5, GSK 744: C19H17F2N3O5.
The dose of GSK744 is 30mg (or less) orally vs. DTG 50mg. Half-life of DTG is 14 hours, GSK744 40 hours.
The injectable nano suspension of 744 (400mg) is detectable up to 48 weeks..
-
The difference seems to be tiny, :) but they have different formulas: DTG
C20H19F2N3O5, GSK 744: C19H17F2N3O5.
The dose of GSK744 is 30mg (or less) orally vs. DTG 50mg. Half-life of DTG is 14 hours, GSK744 40 hours.
The injectable nano suspension of 744 (400mg) is detectable up to 48 weeks..
That explains why they are different, not better. It's basically the same drug retooled as an injectable (which you'll need to take monthly or every couple months).
As far as efficacy or any real difference between the two. Not much.
-
Sounds like the next best thing to buttered toast, however with a heap of potential side effects to boot.
-
My switch was successful so far. Everything's fine with Tivicay/Epzicom for me. I think that You are safe if You dont get SE from Abacavir within the first month.
All-in-one pill should follow soon. The study runs for 3 years. I was told that CAB could be available after these years. But it is still hypothetical.
Dear Mr. Mishma: Do U take all these pills from Your footnote? Can somebody survive this?
-
So the Drug companies are doing the eenee meanee tweaks game again again again